González MAI, Vega RA, Rubio JB

Language: Spanish
References: 29
Page: 25-30
PDF size: 43.13 Kb.

ABSTRACT

Lymphoid cell neoplasms are clonal tumor B cells, T cells or NK cells, 15% of patients developed an episode of thrombosis. The tumors have alterations of hemostasis mainly over-expression tissue factor (TF). Other hemostatic markers [elevated aPTT, PT, D-dimer (DD), fibrinogen degradation products], are altered in patients with lymphomas. Inflammation is recognized as an important biological phenomenon in the presence of cancer biomarkers as proinflammatory cytokines, cell adhesion molecules, metalloproteinases and growth factors. These elements are involved in proliferation, migration, and the tumor microenvironment. Patients with malignancy showed an increase in the prevalence of antiphospholipid antibodies (aPL). Patients with NHL and aPL have a higher incidence of thrombosis when compared with the general population. The procoagulant state in aPL generated under the mechanism of inhibition of natural anticoagulants. This information supports a prothrombotic state that potentially require therapeutic intervention in these patients. The activation of the biological system of inflammation combined with the presence of circulating antibodies in some patients implies the need to understand their interactions and implications as important elements in the clinical spectrum of patients with lymphomas.

REFERENCES

1. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112: 4384-4399.

2. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar ZS, Chanock SJ, Cerhan JR, Hartge P. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008; 112(13): 5150-5160.

3. Falanga A. Thrombophilia in cancer. Semin Thromb Haemost 2005; 31: 104-110.

4. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, Iacoviello L, Donati MB. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18,018 patients and 1,149 events. Blood 2010; 115(26): 5322-5328.

5. Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KLI, Fisher RI, Francis CW. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leukemia Lymphoma 2006; 47: 1029-1033.

6. Kwaan HC, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Haemost 2003; 29(3): 283-290.

7. Kyrle PA. Eichinger sabine. Deep vein thrombosis. Lancet 2005; 365: 1163-1174.

8. Rickles FR, Steven PS, Fernández PM. Tissue factor, thrombin and cancer. Chest 2003; 124: 58S-68S.

9. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005; 92 (8): 1349-1351.

10. López-Pedrera C, Barbarrola N, Velasco F. Patogenia de la trombosis asociada a enfermedades neoplásicas: implicaciones terapéuticas. Med Clin (Barc) 2004; 122(5): 190-196.

11. Day SM, Reeve JL, Pedersen B et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-198.

12. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.

13. Wang J., Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. British Journal of Haematology 2001; 115: 382-391.

14. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005; 257: 209-223.

15. Mackman N. Role of tissue factor in hemostasis, thrombosis and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.

16. Wada H, Sase T, Yamaguchi M. Hypercoagulant status in malignant lymphoma. Exp Oncol 2005; 27(3): 178-185.

17. Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003; 98: 1239-1242.

18. Rubio-Jurado B, Salazar PM, Medrano MF, González OA, Nava A. Trombofilia, autoinmunidad tromboprofilaxis postoperatoria. Cir Ciruj 2007; 75: 313-323.

19. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9(4): 351-369.

20. Balkwill FR. The chemokines system and cancer. The Journal of Pathology 2001. Accepted Article: DOI: 10.1002/pat.3029.

21. Golay J, Introna M. Chemokines and antagonists in non-Hodgkin’s lymphoma. Expert Opin Ther Targets 2008; 12(5): 621-635.

22. Bernard MP, Bancos S, Sime PJ, Phipps RP. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 2008; 14(21): 2051-2060.

23. Bairey O, Blickstein D, Monselise Y, Lahav J, Stark P, Prokocimer M, Nativ HM, Kirgner I, Pazgal I, Shaklai M. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 2006; 76: 384-391.

24. Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 2006; 25: 840-844.

25. Wada H, Sase T, Yamaguchi M. Hypercoagulant status in malignant lymphoma. Exp Oncol 2005; 27(3): 178-185.

26. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospolipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12: 112-116.

27. De Groot PG, Derksenp R. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2007; 3: 1854-1860.

28. Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood 2011; 117(23): 6383-6391.

29. Pierangeli S, Chen PP, González EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13: 366-375.